Tech Company Financing Transactions
Nutcracker Therapeutics Funding Round
On 9/25/2020, Nutcracker Therapeutics received $60 million in Series B funding from Arch Venture Partners and Bluebird Ventures.
Transaction Overview
Company Name
Announced On
9/25/2020
Transaction Type
Venture Equity
Amount
$60,000,000
Round
Series B
Investors
Arch Venture Partners (Lead Investor) (Robert Nelsen)
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
5858 Horton St. 540
Emeryville, CA 94608
USA
Emeryville, CA 94608
USA
Phone
Website
Email Address
Overview
Nutcracker Therapeutics is bringing the combined power of high-technology engineering and advanced biosynthesis to RNA therapeutics through its push-button mRNA synthesis and formulation platform. Armed with this high-tech advantage, we will advance mRNA therapeutics into the clinic and engage in strategic partnerships with clinical institutions and pharmaceutical/biotech companies.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Igor Khandros
Chief Financial Officer
James Zhu
Chief Operating Officer
Madhavan Balachandran
Chief Technical Officer
Benjamin Eldridge
Vice President
Swami Murugappan
Vice President
Bruce Wu
VP - Bus. Development
Kevin Hambly
VP - Human Resources
Kathryn Blystone
VP - R & D
Samuel Deutsch
Browse more venture capital transactions:
Prev: 9/25/2020: SketchyMedical venture capital transaction
Next: 9/25/2020: Babson Diagnostics venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs